RxDoctor Payments DataLook up a doctor →

Vincent Lee, MD

Family Medicine · Paragould, ARNPI 1639498462

Payments from drug & device makers

$15,862in general payments, 2019–2025

Across 973 payments — averaging $16.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Novo Nordisk$3K
  • AbbVie$1K
  • Amgen$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Pfizer$823
  • plus $5K from 36 others

What the payments were for

  • Food & beverage$15,76599%
  • Education$971%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,862 in reported general payments places this provider in the 95th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$83,841
Medicare patients
97
Services billed
1,325

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide73$88,775
EliquisApixaban69$61,701
JardianceEmpagliflozin62$53,639
FarxigaDapagliflozin Propanediol51$51,267
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$46,730
XareltoRivaroxaban21$20,808
JanuviaSitagliptin Phosphate29$20,033
Tresiba Flextouch U-200Insulin Degludec18$17,527
MyrbetriqMirabegron28$17,516
Nurtec OdtRimegepant Sulfate11$16,766
MovantikNaloxegol Oxalate14$11,137
ArexvyRsvpref3 Antigen/As01e/Pf21$6,335
LinzessLinaclotide11$6,126
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$5,652
Novolog FlexpenInsulin Aspart33$4,289

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,665$88,77573 claims
PfizerEliquis, Nurtec Odt$823$78,46780 claims
Boehringer IngelheimJardiance$195$53,63962 claims
GSKTrelegy Ellipta, Arexvy$706$53,06568 claims
AstraZenecaFarxiga$3,273$51,26751 claims
Johnson & JohnsonXarelto$55$20,80821 claims
MerckJanuvia$180$20,03329 claims
Astellas Pharma US IncMyrbetriq$371$17,51628 claims
AbbVieLinzess$1,330$6,12611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Paragould

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →